https://siftingsignal.com/gisignals/Motility papers worth knowing in GI this week. A SiftingSignal publication.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42387275https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42387275Thu, 09 Jul 2026 16:47:07 +0000Alimentary pharmacology & therapeutics. Where it is available (Japan, India, not the US), a single non-randomized study suggests elobixibat may outperform prucalopride on sustained CSBM in refractory functional constipation, but this is hypothesis-generating and does not change guideline-based US practice, where elobixibat is unavailable.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42392123https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42392123Thu, 09 Jul 2026 16:47:07 +0000The lancet. Gastroenterology & hepatology. Rome V criteria show lower sensitivity (66.1%) compared to Rome IV (78.9%) and Rome III (87.5%) in this secondary care study. No clinical action yet; await further validation and SOC updates.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413530https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413530Thu, 09 Jul 2026 16:47:07 +0000The lancet. Gastroenterology & hepatology. This mechanistic review of gut-barrier restoration (SCFAs, glutamine or tryptophan, probiotics) is hypothesis-generating only; barrier-targeted diet or probiotic therapy for disorders of gut-brain interaction is not yet guideline-supported and should await clinical trials.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413705https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413705Thu, 09 Jul 2026 16:47:07 +0000Gastroenterology. Acupuncture may improve IBS symptoms compared to sham, but the high heterogeneity and low certainty of evidence limit clinical applicability. Discuss these limitations if patients inquire about acupuncture.